Pathophysiological mechanisms of vascular hyporesponsiveness in shock states;Physiopathologie de l'hyporéactivité vasculaire au cours des états de choc

Reanimation

Volumn 17, Issue 2, 2008, Pages 101-110

  Collin, S ^a   Levy, B ^a,b  

^a INSERM   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Nitric oxide; Potassium channels; Shock states; Vasoplegia

Indexed keywords

ACTIVATED PROTEIN C; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENOMEDULLIN; ALPHA ADRENERGIC RECEPTOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; CATECHOLAMINE; DNA; GLIBENCLAMIDE; GLUCOCORTICOID; GUANOSINE PHOSPHATE; HYDROCORTISONE; HYPERTENSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTIC ACID; LIPID; NITRIC OXIDE; PEROXYNITRITE; PLACEBO; POTASSIUM CHANNEL; PROTEIN; SUPEROXIDE; VASOPRESSIN;

ACIDOSIS; CLINICAL STUDY; CONCENTRATION (PARAMETERS); DEATH; DESENSITIZATION; DOWN REGULATION; EXCITABLE MEMBRANE; EXPERIMENTAL STUDY; HEART FAILURE; HEMODYNAMICS; HYPERPOLARIZATION; HYPOTENSION; HYPOVOLEMIA; HYPOXIA; ISCHEMIA; MULTIPLE ORGAN FAILURE; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; SEPSIS; SEPTIC SHOCK; SHORT SURVEY; TISSUE PERFUSION; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; VASOPRESSIN BLOOD LEVEL;

EID: 39949085060     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2007.12.008     Document Type: Short Survey

References (43)

1. Bellissant E., and Annane D. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 68 (2000) 293-303
2. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43 (1991) 109-142
3. Julou-Schaeffer G., Gray G.A., Fleming I., Schott C., Parratt J.R., and Stoclet J.C. Loss of vascular responsiveness induced by endotoxin involves l-arginine pathway. Am J Physiol 259 (1990) H1038-H1043
4. McKenna T.M. Enhanced vascular effects of cyclic GMP in septic rat aorta. Am J Physiol 254 (1988) R436-R442
5. Cobb J.P., and Danner R.L. Nitric oxide and septic shock. JAMA 275 (1996) 1192-1196
6. Mebazaa A., De Keulenaer G.W., Paqueron X., Andries L.J., Ratajczak P., Lanone S., et al. Activation of cardiac endothelium as a compensatory component in endotoxin-induced cardiomyopathy: role of endothelin, prostaglandins and nitric oxide. Circulation 104 (2001) 3137-3144
7. Pacher P., Beckman J.S., and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 (2007) 315-424
8. Walker T.A., Curtis S.E., King-VanVlack C.E., Chapler C.K., Vallet B., and Cain S.M. Effects of nitric oxide synthase inhibition on regional hemodynamics and oxygen transport in endotoxic dogs. Shock 4 (1995) 415-420
9. Vincent J.L., Zhang H., Szabo C., and Preiser J.C. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 161 (2000) 1781-1785
10. Grover R., Zaccardelli D., Colice G., Guntupalli K., Watson D., and Vincent J.L. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-l-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 27 (1999) 913-922
11. Lopez A., Lorente J.A., Steingrub J., Bakker J., McLuckie A., Willatts S., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32 (2004) 21-30
12. Levy B., Valtier M., de Chillou C., Bollaert P.E., Cane D., and Mallie J.P. Beneficial effects of l-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. Shock 11 (1999) 98-103
13. Pacher P., and Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 25 (2007) 235-260
14. Macarthur H., Westfall T.C., Riley D.P., Misko T.P., and Salvemini D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci USA 97 (2000) 9753-9758
15. + channels in smooth muscle. J Physiol 572 (2006) 617-624
16. Buckley J.F., Singer M., and Clapp L.H. Role of KATP channels in sepsis. Cardiovasc Res 72 (2006) 220-230
17. + channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89 (1992) 2071-2074
18. Czaika G., Gingras Y., Zhu E., and Comtois A.S. Induction of the ATP-sensitive potassium (uK(ATP)-1) channel by endotoxemia. Muscle Nerve 23 (2000) 967-969
19. Warrillow S., Egi M., and Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 34 (2006) 980-985
20. Morelli A., Lange M., Ertmer C., Broeking K., Van Aken H., Orecchioni A., et al. Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. Shock 28 5 (2007) 530-535
21. Cauwels A., and Brouckaert P. Critical role for small and large conductance calcium-dependent potassium channels in endotoxemia and Tnf toxicity. Shock (2007) Publish ahead of print
22. Pickkers P., Dorresteijn M.J., Bouw M.P., van der Hoeven J.G., and Smits P. In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation 114 (2006) 414-421
23. Landry D.W., Levin H.R., Gallant E.M., Ashton Jr. R.C., Seo S., D'Alessandro D., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997) 1122-1125
24. Sharshar T., Carlier R., Blanchard A., Feydy A., Gray F., Paillard M., et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 30 (2002) 497-500
25. Holmes C.L., Patel B.M., Russell J.A., and Walley K.R. Physiology of vasopressin relevant to management of septic shock. Chest 120 (2001) 989-1002
26. Leone M., and Boyle W.A. Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 34 (2006) 1126-1130
27. Hollenberg S.M., Tangora J.J., Piotrowski M.J., Easington C., and Parrillo J.E. Impaired microvascular vasoconstrictive responses to vasopressin in septic rats. Crit Care Med 25 (1997) 869-873
28. Barrett L.K., Orie N.N., Taylor V., Stidwill R.P., Clapp L.H., and Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 35 (2007) 2337-2343
29. McMillan M., Chernow B., and Roth B.L. Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsis. Circ Shock 19 (1986) 185-193
30. Fowler D.E., and Wang P. The cardiovascular response in sepsis: proposed mechanisms of the beneficial effect of adrenomedullin and its binding protein (review). Int J Mol Med 9 (2002) 443-449
31. Gonzalez-Rey E., Chorny A., Varela N., Robledo G., and Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol 168 (2006) 1921-1930
32. Miksa M., Wu R., Cui X., Dong W., Das P., Simms H.H., et al. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-{gamma}. J Immunol 179 (2007) 6263-6272
33. Breslow M.J., and Ligier B. Hyperadrenergic states. Crit Care Med 19 (1991) 1566-1579
34. Clutter W.E., Bier D.M., Shah S.D., and Cryer P.E. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 66 (1980) 94-101
35. Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B., Korach J.M., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
36. Oppert M., Schindler R., Husung C., Offermann K., Graf K.J., Boenisch O., et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33 (2005) 2457-2464
37. Prigent H., Maxime V., and Annane D. Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 8 (2004) 243-252
38. Kilger E., Weis F., Briegel J., Frey L., Goetz A.E., Reuter D., et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 31 (2003) 1068-1074
39. Isobe H., Okajima K., Uchiba M., Mizutani A., Harada N., Nagasaki A., et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104 (2001) 1171-1175
40. Regnault V., and Levy B. Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy?. Crit Care 11 (2007) 103
41. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
42. Monnet X., Lamia B., Anguel N., Richard C., Bonmarchand G., and Teboul J.L. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 31 (2005) 1573-1576
43. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368-1377